Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 20;1-2.
doi: 10.1007/s10549-020-05674-7. Online ahead of print.

Treatment Options for Patients With HR+/HER2- Advanced Breast Cancer During the COVID-19 Pandemic: Dose Reduction of Ribociclib Does Not Diminish Efficacy

Affiliations
Free PMC article

Treatment Options for Patients With HR+/HER2- Advanced Breast Cancer During the COVID-19 Pandemic: Dose Reduction of Ribociclib Does Not Diminish Efficacy

Joyce O'Shaughnessy. Breast Cancer Res Treat. .
Free PMC article

Conflict of interest statement

Dr. O’Shaughnessy reports AbbVie Inc., Agendia, Amgen Biotechnology, AstraZeneca, Bristol-Myers Squibb, Celgene Corporation, Eisai, Genentech, Genomic Health, GRAIL, Immunomedics, Heron Therapeautics, Ipsen Biopharmaceuticals, Jounce Therapeutics, Lilly, Merck, Myriad, Novartis, Ondonate Therapeutics, Pfizer, Puma Biotechnology, Prime Oncology, Roche, Seattle Genetics, Syndax Pharmaceuticals.

Comment on

  • Breast Cancer Res Treat. doi: 10.1007/s10549-020-05644-z

Similar articles

See all similar articles

References

    1. Deitz JR, Moran MS, Isakoff SJ, et al. Recommendations for prioritization, treatment and triage of breast cancer patients during the COVID-19 pandemic. Breast Cancer Res Treat. 2020 doi: 10.1007/s10549-020-05644-z. - DOI
    1. Beck JT, Neven P, Sohn J, et al. Ribociclib treatment benefit in patients with advanced breast cancer with ≥1 dose reduction: Data from the MONALEESA-2, -3, and -7 trials. Cancer Res. 2019;79(4S):P6-18-06.
    1. NCCN Clinical Practice Guidelines in Oncology for Breast Cancer V.3.2020.
Feedback